Paul Saladino· MD
similarly the risk for neurocognitive events was nonstatic statistically significantly increased in the lipid lowering and clinical outcome studies
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
similarly the risk for neurocognitive events was nonstatic statistically significantly increased in the lipid lowering and clinical outcome studies
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
the risk of death was not significantly different between the pcsk9 inhibitor versus placebo groups in the lipid lowering studies and clinical outcome studies
the risk for diabetes malius was non statistically significantly increased in the pcsk9 inhibitor versus placebo groups in the lipid lowering studies and clinical outcome studies